Retrospective analysis of THRLBCL reveals similar survival outcomes despite socioeconomic differences in U.S. cohorts.
Key Points
Overall survival rates were similar for patients treated at ACPs and CCPs, indicating effective care delivery across settings.
Analysis included 1,938 THRLBCL patients, of which 894 were treated at ACPs and 632 at CCPs, showcasing demographic disparities.
Employing Kaplan-Meier and Cox models, the study adjusted for variables impacting overall survival and demographic profiles.
Findings suggest standardized treatment approaches can ensure uniform outcomes in T-cell/histiocyte-rich large B-cell lymphoma across various facilities.